EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Sustained improvements in health status and work productivity with bimekizumab in psoriatic arthritis: 2-year results from two phase 3 studies

William Tillett iD, Laure Gossec iD, M Elaine Husni iD, Akimichi Morita iD, Barbara Ink, Rajan Bajracharya iD, Patrick Healy, Michael F Mørup iD, Jessica A Walsh iD

Rheumatology Advances in Practice · 02.01.2026 · 10 (1)

DOI: 10.1093/rap/rkag009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Rheumatology Advances in Practice, online erschienen am 25.01.2026. Verfasst von William Tillett und 8 weiteren Autor:innen. Beteiligte Einrichtung: Royal National Hospital of Rheumatic Diseases, Bath, UK. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Lilit Ghazaryan and Aditi Mehta, both of Costello Medical, London, UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To assess the 2-year impact of bimekizumab on health status, work productivity and indirect cost savings in patients with active PsA.

Methods

BE OPTIMAL [NCT03895203; biologic disease-modifying anti-rheumatic drug (bDMARD)-naïve] and BE COMPLETE [NCT03896581; tumor necrosis factor inhibitor inadequate response/intolerance (TNFi-IR)] assessed subcutaneous bimekizumab 160 mg every 4 weeks. BE OPTIMAL week 52/BE COMPLETE week 16 completers could enter BE VITAL (NCT04009499; open-label extension), where all patients received bimekizumab. Outcomes reported for placebo- and bimekizumab-randomized patients to year 2 were changes in health status (EQ-5D-3L) and work productivity [Work Productivity and Activity Impairment Questionnaire—Specific Health Problem v2.0 (WPAI-SHP)], associations between disease control criteria and WPAI-SHP, and annualized indirect cost savings (estimated by multiplying 2022 average wages by improvements in overall work impairment). Missing data were imputed using multiple (continuous) or non-responder (binary) imputation.

Results

Among 712 bDMARD-naïve and 400 TNFi-IR patients, improvements from baseline in mean EQ-5D-3L visual analog scale scores were sustained to year 2, with scores improving by 24.6–38.9%. A minimal clinically important difference in overall work impairment was achieved by 51.1–64.8% of patients at year 1, and this was largely sustained to year 2 (44.3–51.6%). The greatest work productivity improvements were observed in patients who achieved stringent disease control across both musculoskeletal and skin domains. In Europe, indirect cost savings at year 1 (US$7965–11 517) were sustained to year 2 (US$7789–12 018); trends were similar in the USA and Japan.

Conclusion

Bimekizumab treatment resulted in sustained improvements in health status and work productivity to year 2, with substantial potential for long-term indirect cost savings, regardless of prior TNFi experience.

Schlagwörter

Stichwörter der Autor:innen

IL-17bimekizumabcost savingshealth statuspsoriatic arthritiswork productivity

Autor:innen und Institutionen

  • Royal National Hospital of Rheumatic Diseases, Bath, UK.
  • Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, UK.
  • Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France.
  • Rheumatology Department, AP-HP, Pitié-Salpêtrière Hospital, Paris, France.
  • Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, USA.
  • Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

ORCID-Profile: William Tillett, Laure Gossec, M Elaine Husni, Akimichi Morita, Rajan Bajracharya, Michael F Mørup, Jessica A Walsh

Förderung

  • Lilit Ghazaryan and Aditi Mehta, both of Costello Medical, London, UK

Zitieren

APA

Tillett, W., Gossec, L., Husni, M. E., Morita, A., Ink, B., Bajracharya, R., Healy, P., Mørup, M. F., & Walsh, J. A. (2026). Sustained improvements in health status and work productivity with bimekizumab in psoriatic arthritis: 2-year results from two phase 3 studies. Rheumatology Advances in Practice, 10(1). https://doi.org/10.1093/rap/rkag009

Vancouver

Tillett W, Gossec L, Husni ME, Morita A, Ink B, Bajracharya R, et al. Sustained improvements in health status and work productivity with bimekizumab in psoriatic arthritis: 2-year results from two phase 3 studies. Rheumatology Advances in Practice. 2026;10(1). doi:10.1093/rap/rkag009

BibTeX
@article{Tillett2026,
  author = {Tillett, William and Gossec, Laure and Husni, M Elaine and Morita, Akimichi and Ink, Barbara and Bajracharya, Rajan and Healy, Patrick and Mørup, Michael F and Walsh, Jessica A},
  title = {Sustained improvements in health status and work productivity with bimekizumab in psoriatic arthritis: 2-year results from two phase 3 studies},
  journal = {Rheumatology Advances in Practice},
  year = {2026},
  volume = {10},
  number = {1},
  doi = {10.1093/rap/rkag009}
}
Kostenlos starten →